Share This Page
Drug Price Trends for SM MIGRAINE
✉ Email this page to a colleague
Average Pharmacy Cost for SM MIGRAINE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM MIGRAINE 250-250-65 MG CPLT | 70677-0119-01 | 0.06420 | EACH | 2025-02-19 |
| SM MIGRAINE 250-250-65 MG CPLT | 70677-0119-01 | 0.06280 | EACH | 2025-01-22 |
| SM MIGRAINE 250-250-65 MG CPLT | 70677-0119-01 | 0.06407 | EACH | 2024-12-18 |
| SM MIGRAINE 250-250-65 MG CPLT | 70677-0119-01 | 0.06295 | EACH | 2024-11-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Migraine Drugs
Introduction to the Migraine Drugs Market
The migraine drugs market is a rapidly growing sector driven by advancements in treatment processes, increasing prevalence of migraines, and the adoption of novel therapies. Here, we will delve into the market analysis, key drivers, and price projections for migraine drugs.
Current Market Size and Growth Projections
As of 2023, the migraine drugs market size was valued at approximately $4.2 billion. It is projected to grow to $6.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% during the 2024-2032 period[1].
On a broader scale, the migraine market across seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is expected to reach $16.4 billion by 2033, growing at a CAGR of 6.0% from $9.2 billion in 2023[3].
Key Drivers of Market Growth
Advancements in Novel Therapies
The market is significantly driven by the adoption of calcitonin gene-related peptide (CGRP) inhibitors, such as Aimovig and Emgality. These drugs target the CGRP to reduce migraine frequency and have shown promising results in clinical trials[1][3].
Increasing Prevalence of Migraines
Migraines are a leading cause of disability globally, and their increasing prevalence is a major driver of the market. The condition affects a significant portion of the population, with women being more commonly affected due to hormonal changes[4].
Geographic Market Share
North America currently holds the largest market share due to high healthcare spending and the presence of major pharmaceutical companies. Europe and Asia-Pacific also represent significant markets, with Asia-Pacific expected to witness substantial growth due to improving healthcare infrastructure and increasing demand for better healthcare facilities[1][4].
Economic Burden of Migraines
Migraines impose a substantial economic burden on both individuals and employers. In the United States, the total indirect cost associated with migraines is estimated at $19.3 billion, with direct healthcare costs for individuals with migraines averaging $22,364 per person annually, significantly higher than those without migraines[2].
Types of Migraine Drugs
Abortive Medicines
These drugs are used to treat migraine symptoms once they occur. They include triptans (serotonin receptor agonists), ergotamine derivatives, and others. Abortive medicines dominated the market in 2017 due to their ease of self-administration, especially for patients experiencing nausea and vomiting[4].
Preventive Medicines
These drugs are used to reduce the frequency and severity of migraines. They include anticonvulsants, antidepressants, beta blockers, and CGRP inhibitors. The development of CGRP inhibitors has been a significant advancement in preventive treatment[4].
Route of Administration and Distribution Channels
Migraine drugs are administered through various routes, including oral, injection, and others. Distribution channels include hospital-based pharmacies, retail pharmacies, and online pharmacies. The ease of access through these channels contributes to the market's growth[4].
Price Projections and Cost Considerations
CGRP Inhibitors
CGRP inhibitors, such as those used for preventive treatment, can be costly. For example, one type of CGRP migraine treatment costs approximately $6,900 per year or $575 per month. Despite the higher costs, these treatments are gaining traction due to their efficacy[5].
Reimbursement and Insurance
The high costs of CGRP inhibitors are often mitigated by health insurance coverage. However, reimbursement restrictions and patent expiries of branded drugs may impact their long-term market presence[3].
Regional Market Analysis
- North America: This region holds the largest market share due to high healthcare spending and the presence of major pharmaceutical companies.
- Europe: Europe is another significant market, with countries like Germany, France, and the UK contributing substantially.
- Asia-Pacific: This region is expected to witness significant growth due to improving healthcare infrastructure and increasing demand for better healthcare facilities[1][4].
Challenges and Opportunities
Side Effects and Long-Term Risks
While CGRP inhibitors offer effective treatment, they may come with side effects such as sleepiness, nausea, dry mouth, abdominal pain, and upset stomach. Long-term risks are still being studied, which could impact market growth[5].
Emerging Markets
The focus on emerging markets, particularly in Asia-Pacific and Latin America, presents new opportunities for market growth. These regions offer untapped potential for pharmaceutical companies looking to expand their presence[4].
Key Takeaways
- The migraine drugs market is expected to grow significantly, driven by advancements in CGRP inhibitors and increasing prevalence of migraines.
- North America holds the largest market share, followed by Europe and Asia-Pacific.
- CGRP inhibitors are costly but effective, with potential long-term risks that need further research.
- Emerging markets offer significant growth opportunities for pharmaceutical companies.
Frequently Asked Questions (FAQs)
Q: What is the projected market size of the migraine drugs market by 2032? A: The migraine drugs market is expected to reach $6.3 billion by 2032[1].
Q: What are the key drivers of the migraine drugs market? A: The market is driven by advancements in novel therapies, particularly CGRP inhibitors, and the increasing prevalence of migraines[1][3].
Q: How much do CGRP inhibitors cost? A: CGRP inhibitors can cost approximately $6,900 per year or $575 per month[5].
Q: Which region holds the largest market share in the migraine drugs market? A: North America holds the largest market share due to high healthcare spending and the presence of major pharmaceutical companies[1].
Q: What are the potential long-term risks associated with CGRP inhibitors? A: The long-term risks of CGRP inhibitors are still being studied, but they may include side effects such as sleepiness, nausea, and abdominal pain[5].
Cited Sources:
- Biospace: Migraine Drugs Market Size to Reach USD 6.3 Billion by 2032 ...
- The American Journal of Managed Care: Estimating the Economic Burden of Migraine on US Employers
- Clinical Trials Arena: Migraine market expected to reach $16.4bn across 7MM by 2033
- Allied Market Research: Migraine Drugs Market Size, Share & Report 2035
- Healthline: CGRP Migraine Treatment: Could It Be Right for You?
More… ↓
